SG11201408641UA - Phenoxyethyl piperidine compounds - Google Patents
Phenoxyethyl piperidine compoundsInfo
- Publication number
- SG11201408641UA SG11201408641UA SG11201408641UA SG11201408641UA SG11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indiana
- indianapolis
- company
- eli lilly
- Prior art date
Links
- RSUFKEGMFFPMIB-UHFFFAOYSA-N 1-(2-phenoxyethyl)piperidine Chemical class C=1C=CC=CC=1OCCN1CCCCC1 RSUFKEGMFFPMIB-UHFFFAOYSA-N 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/004229 A1 (51) International Patent Classification: C07D 211/60 (2006.01) A61P19/00 (2006.01) A61K31/45 (2006.01) A61P 29/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/046684 20 June 2013 (20.06.2013) English (30) Priority Data: 61/665,951 61/779,099 29 June 2012 (29.06.2012) 13 March 2013 (13.03.2013) English US US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: SCHIFFLER, Matthew Allen; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). YORK, Jeremy Schulenburg; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agents: LENTZ, Nelsen L. et al.; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206- 6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: PHENOXYETHYL PIPERIDINE COMPOUNDS C0 H 2 Formula II wherein X is: 0\ CJ CJ •t o o H C a , or O CJ o & (57) Abstract: The present invention provides a compound of the Formula II: Formula wherein II X is: R 1 is H, -CN, or F; R 2 is H or methyl; R 3 is H; and R is 4 H, methyl, or ethyl; or R 3 and R 4 joined together form a cyclopropyl ring; or a pharmaceutically accept able salt thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665951P | 2012-06-29 | 2012-06-29 | |
| US201361779099P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/046684 WO2014004229A1 (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408641UA true SG11201408641UA (en) | 2015-01-29 |
Family
ID=48746666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408641UA SG11201408641UA (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Country Status (42)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (en) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | Phenoxyethyl piperidine compounds |
| TWI636046B (en) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | Phenoxyethyl dihydro-1h-isoquinoline compounds |
| RS56615B1 (en) * | 2013-12-17 | 2018-02-28 | Lilly Co Eli | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
| CR20180323A (en) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS |
| CN110621671A (en) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | Benzofuran and benzothiophene derivatives as PGE2 receptor modulators |
| PE20191811A1 (en) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS |
| PE20191814A1 (en) | 2017-05-18 | 2019-12-27 | Idorsia Pharmaceuticals Ltd | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS |
| JP7065117B2 (en) | 2017-05-18 | 2022-05-11 | イドーシア ファーマシューティカルズ リミテッド | N-substituted indole derivative |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| JP7488269B2 (en) * | 2019-01-22 | 2024-05-21 | キーセラ・（スーチョウ）・ファーマシューティカルズ・カンパニー・リミテッド | Compounds that inhibit PGE2/EP4 signal transduction, their preparation method and their application in medicine |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (en) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-acyl-4- (2-aminoethyl) benzoic acids, their salts and esters, process for their preparation and their use |
| CA2478653A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| JP2006515015A (en) * | 2003-01-10 | 2006-05-18 | エフ．ホフマン−ラ ロシュ アーゲー | 2-Piperidone derivatives as prostaglandin agonists |
| WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| US20050105732A1 (en) | 2003-11-17 | 2005-05-19 | Hutchings George T. | Systems and methods for delivering pre-encrypted content to a subscriber terminal |
| BRPI0510598A (en) * | 2004-05-04 | 2007-11-20 | Pfizer | substituted aryl or heteroaryl amide compounds |
| AU2005238291A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| EP2013169B1 (en) | 2006-04-24 | 2012-08-22 | Merck Canada Inc. | Indole amide derivatives as ep4 receptor antagonists |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| WO2008092860A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| SI2565191T1 (en) | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| CN102149384B (en) | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | Heterocyclic amide derivatives as EP4 receptor antagonists |
| CN107693518A (en) | 2010-02-22 | 2018-02-16 | 株式会社ＡｓｋＡｔ | Purposes of the receptor antagonists of EP 4 in treatment IL 23 is disease mediated |
| HRP20170042T1 (en) * | 2010-09-21 | 2017-03-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| US9120824B2 (en) * | 2011-07-04 | 2015-09-01 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor agonists |
| CN103702980B (en) * | 2011-07-04 | 2016-10-05 | 罗达制药生物技术有限责任公司 | Cyclic amine derivatives as EP4 receptor antagonists |
| JO3296B1 (en) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | Phenoxyethyl piperidine compounds |
-
2013
- 2013-06-13 JO JOP/2013/0177A patent/JO3296B1/en active
- 2013-06-13 AR ARP130102076 patent/AR091429A1/en active IP Right Grant
- 2013-06-14 TW TW102121220A patent/TWI599561B/en active
- 2013-06-20 JP JP2015520304A patent/JP6127136B2/en active Active
- 2013-06-20 AP AP2014008164A patent/AP2014008164A0/en unknown
- 2013-06-20 EP EP13734248.1A patent/EP2867207B1/en active Active
- 2013-06-20 KR KR1020147036137A patent/KR101653476B1/en active Active
- 2013-06-20 CN CN201380034168.8A patent/CN104411684B/en active Active
- 2013-06-20 CA CA2875569A patent/CA2875569C/en active Active
- 2013-06-20 BR BR112014031616-3A patent/BR112014031616B1/en active IP Right Grant
- 2013-06-20 NZ NZ701933A patent/NZ701933A/en unknown
- 2013-06-20 UA UAA201413598A patent/UA114325C2/en unknown
- 2013-06-20 LT LTEP13734248.1T patent/LT2867207T/en unknown
- 2013-06-20 SI SI201330755T patent/SI2867207T1/en unknown
- 2013-06-20 HU HUE13734248A patent/HUE034425T2/en unknown
- 2013-06-20 EA EA201492255A patent/EA024392B1/en not_active IP Right Cessation
- 2013-06-20 WO PCT/US2013/046684 patent/WO2014004229A1/en not_active Ceased
- 2013-06-20 MX MX2014015953A patent/MX345324B/en active IP Right Grant
- 2013-06-20 HR HRP20171515TT patent/HRP20171515T1/en unknown
- 2013-06-20 MA MA37686A patent/MA37686B1/en unknown
- 2013-06-20 RS RS20171039A patent/RS56452B1/en unknown
- 2013-06-20 US US13/922,278 patent/US8962659B2/en active Active
- 2013-06-20 ES ES13734248.1T patent/ES2644812T3/en active Active
- 2013-06-20 SG SG11201408641UA patent/SG11201408641UA/en unknown
- 2013-06-20 AU AU2013280875A patent/AU2013280875B2/en active Active
- 2013-06-20 MY MYPI2014703971A patent/MY173878A/en unknown
- 2013-06-20 PT PT137342481T patent/PT2867207T/en unknown
- 2013-06-20 PL PL13734248T patent/PL2867207T3/en unknown
- 2013-06-20 DK DK13734248.1T patent/DK2867207T3/en active
- 2013-06-20 PE PE2014002532A patent/PE20150182A1/en active IP Right Grant
- 2013-06-20 ME MEP-2017-223A patent/ME02840B/en unknown
-
2014
- 2014-11-24 ZA ZA2014/08632A patent/ZA201408632B/en unknown
- 2014-11-27 CO CO14261550A patent/CO7151507A2/en unknown
- 2014-11-28 TN TN2014000501A patent/TN2014000501A1/en unknown
- 2014-12-03 CR CR20140553A patent/CR20140553A/en unknown
- 2014-12-11 IL IL236219A patent/IL236219A/en active IP Right Grant
- 2014-12-17 GT GT201400288A patent/GT201400288A/en unknown
- 2014-12-17 DO DO2014000287A patent/DOP2014000287A/en unknown
- 2014-12-26 CL CL2014003535A patent/CL2014003535A1/en unknown
- 2014-12-29 EC ECIEPI201433267A patent/ECSP14033267A/en unknown
-
2015
- 2015-01-05 PH PH12015500009A patent/PH12015500009B1/en unknown
- 2015-01-13 US US14/595,350 patent/US9402838B2/en active Active
-
2017
- 2017-09-15 CY CY20171100979T patent/CY1119425T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201901197PA (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408261UA (en) | Syringe | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201408511QA (en) | Liquid preparations of amines and organic acids stabilized by salts | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators |